{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:33:09Z","timestamp":1791923589154,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00406-013-0419-y","type":"journal-article","created":{"date-parts":[[2013,7,8]],"date-time":"2013-07-08T05:07:44Z","timestamp":1373260064000},"page":"131-141","source":"Crossref","is-referenced-by-count":40,"title":["Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study"],"prefix":"10.1007","volume":"264","author":[{"given":"R.","family":"Grohmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"R\u00fcther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"D Allison","year":"1999","unstructured":"Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, Weiden P (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686\u20131696","journal-title":"Am J Psychiatry"},{"key":"419_CR2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1192\/bjp.124.5.413","volume":"124","author":"P Beamont","year":"1974","unstructured":"Beamont P, Gleder M, Friesen H, Harris G, MacKinnon B, Mandelbrote B (1974) The effects of phenothiazines on endocrine function. Patients with inadequate lactation and amenorrhea. Br J Psychiatry 124:413\u2013419","journal-title":"Br J Psychiatry"},{"key":"419_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00023210-199912030-00002","volume":"12","author":"PL Canales","year":"1999","unstructured":"Canales PL, Olsen J, Miller AL et al (1999) Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 12:179\u2013188","journal-title":"CNS Drugs"},{"key":"419_CR4","first-page":"12","volume":"63","author":"SN Caroff","year":"2002","unstructured":"Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002) Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 63:12\u201319","journal-title":"J Clin Psychiatry"},{"key":"419_CR5","first-page":"79","volume":"41","author":"SN Caroff","year":"1980","unstructured":"Caroff SN (1980) The neuroleptic malignant syndrome. J Clin Psychiatry 41:79\u201383","journal-title":"J Clin Psychiatry"},{"key":"419_CR6","first-page":"70","volume":"45","author":"E Cicarelli","year":"2001","unstructured":"Cicarelli E, Razzore P, Gaia D (2001) Hyperprolactin\u00e4mia and provatine in benign intracranial tumors. J Neurosurg Sci 45:70","journal-title":"J Neurosurg Sci"},{"key":"419_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","volume":"159","author":"CR Dolder","year":"2002","unstructured":"Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103\u2013108","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"419_CR8","first-page":"12","volume":"37","author":"RR Engel","year":"2004","unstructured":"Engel RR, Grohmann R, R\u00fcther E, Hippius H (2004) Research methods in drug surveillance. Pharmacopsychiatry 37(Suppl 1):12\u201315","journal-title":"Pharmacopsychiatry"},{"key":"419_CR9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","volume":"65","author":"R Ganguly","year":"2004","unstructured":"Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998\u20132000. J Clin Psychiatry 65:1377\u20131388","journal-title":"J Clin Psychiatry"},{"key":"419_CR10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686\u2013693","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"419_CR11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1055\/s-2004-832684","volume":"37","author":"WF Gattaz","year":"2004","unstructured":"Gattaz WF, Diehl A, Geuppert MS et al (2004) Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37(Suppl 1):279\u2013285","journal-title":"Pharmacopsychiatry"},{"key":"419_CR12","first-page":"9","volume-title":"Flupentixol","author":"T Glaser","year":"1998","unstructured":"Glaser T, Sommermeyer H, Fa\u00dfbender M, Mauler F (1998) Das Rezeptorbindungsprofil von cis-Flupentixol. In: Glaser T, Soyka M (eds) Flupentixol. Steinkopff Verlag, Darmstadt, pp 9\u201320"},{"issue":"Suppl 1","key":"419_CR13","first-page":"27","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, Geissler KH, R\u00fcther E (2004) Psychotropic drug use in psychiatric inpatients: recent trends and changes over time\u2014data from the AMSP study. Pharmacopsychiatry 37(Suppl 1):27\u201338","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"419_CR14","first-page":"4","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, R\u00fcther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):4\u201311","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"419_CR15","first-page":"16","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Hippius H, Helmchen H, R\u00fcther E, Schmidt LG (2004) The AM\u00dcP study for drug surveillance in psychiatry\u2014a summary of inpatient data. Pharmacopsychiatry 37(Suppl 1):16\u201326","journal-title":"Pharmacopsychiatry"},{"key":"419_CR16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-79126-0","volume-title":"Unerw\u00fcnschte Wirkungen von Psychopharmaka","author":"R Grohmann","year":"1994","unstructured":"Grohmann R, R\u00fcther E (1994) Neuroleptika. In: Grohmann R, R\u00fcther E, Schmidt LG (eds) Unerw\u00fcnschte Wirkungen von Psychopharmaka. Springer, Berlin, pp 43\u2013133"},{"key":"419_CR17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/j.1875-9114.1991.tb02660.x","volume":"11","author":"AJ Gruber","year":"1991","unstructured":"Gruber AJ, Cole JO (1991) Antidepressant effects of flupentixol. Pharmacotherapy 11:450\u2013459","journal-title":"Pharmacotherapy"},{"key":"419_CR18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0031-1286282","volume":"44","author":"G Gr\u00fcnder","year":"2011","unstructured":"Gr\u00fcnder G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236\u2013248","journal-title":"Pharmacopsychiatry"},{"key":"419_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00023210-199810030-00005","volume":"10","author":"M Hamner","year":"1998","unstructured":"Hamner M, Arana G (1998) Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 10:209\u2013222","journal-title":"CNS Drugs"},{"key":"419_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000068874","volume":"47","author":"I Hertling","year":"2003","unstructured":"Hertling I, Philipp M, Dvorak A et al (2003) Flupentixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47:37\u201346","journal-title":"Neuropsychobiology"},{"key":"419_CR21","first-page":"501","volume":"13","author":"H Hippius","year":"1958","unstructured":"Hippius H, Kanig K (1958) Die Agranulocytose unter neuro-psychiatrischer Phenothiazin-Therapie. \u00c4rztl Wochenschrift 13:501\u2013507","journal-title":"\u00c4rztl Wochenschrift"},{"key":"419_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00606409","volume":"11","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193\u2013198","journal-title":"Eur J Clin Pharmacol"},{"key":"419_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Engel RR, Davies JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31\u201341","journal-title":"Lancet"},{"key":"419_CR24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123\u2013136","journal-title":"Schizophr Res"},{"key":"419_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2008-1076727","volume":"41","author":"EM Meisenzahl","year":"2008","unstructured":"Meisenzahl EM, Schmitt G, Gr\u00fcnder G, Dresel S, Frodl T, la Foug\u00e8re C, Scheuerecker J, Schwarz M, Boerner R, Strauss J, Hahn K, M\u00f6ller HJ (2008) Striatal D2\/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41:169\u2013175","journal-title":"Pharmacopsychiatry"},{"key":"419_CR26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4088\/JCP.v63n0915e","volume":"63","author":"H Nasrallah","year":"2002","unstructured":"Nasrallah H, Tandon R (2002) Efficacy, safety and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 63:12\u201320","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"419_CR27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0269881103017002012","volume":"17","author":"C Paton","year":"2003","unstructured":"Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R (2003) Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 17(2):223\u2013229","journal-title":"J Psychopharmacol"},{"key":"419_CR28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.pnpbp.2007.02.014","volume":"31","author":"S Ruhrmann","year":"2007","unstructured":"Ruhrmann S, Kissling W, Lesch OW et al (2007) Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry 31:1012\u20131022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"419_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindings. Psychopharmacology 124:57\u201373","journal-title":"Psychopharmacology"},{"issue":"Suppl 1","key":"419_CR30","first-page":"54","volume":"37","author":"S St\u00fcbner","year":"2004","unstructured":"St\u00fcbner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neund\u00f6rfer G, M\u00f6ller HJ, Hippius H, R\u00fcther E (2004) Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37(Suppl 1):54\u201364","journal-title":"Pharmacopsychiatry"},{"key":"419_CR31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jcem.83.2.4564","volume":"83","author":"P Touraine","year":"1998","unstructured":"Touraine P, Martini J, Zafrani B (1998) Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667","journal-title":"J Clin Endocrinol Metab"},{"key":"419_CR32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","volume":"65","author":"J Volavka","year":"2004","unstructured":"Volavka J, Czobor P, Cooper T, Sheitman B, Lindenmayer P, Citrome L, McEvoy J, Lieberman J (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidon or haloperidol. J Clin Psychiatry 65:57\u201361","journal-title":"J Clin Psychiatry"},{"key":"419_CR33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809\u2013824","journal-title":"Stat Med"},{"key":"419_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00002018-200124010-00005","volume":"24","author":"T Wetterling","year":"2001","unstructured":"Wetterling T (2001) Bodyweight gain with atypical antipsychotics. Drug Saf 24:59\u201373","journal-title":"Drug Saf"},{"key":"419_CR35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","volume":"324","author":"A Wieck","year":"2002","unstructured":"Wieck A, Haddad P (2002) Hyperprolactinemia caused by antipsychotic drugs. BMJ 324:250\u2013252","journal-title":"BMJ"},{"issue":"9","key":"419_CR36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pds.1781","volume":"18","author":"MU Yood","year":"2009","unstructured":"Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L\u2019Italien G (2009) The incidence of diabetes in atypical antipsychotic users differs according to agent\u2014results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 18(9):791\u2013799","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-013-0419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-013-0419-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-013-0419-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:12:46Z","timestamp":1715649166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-013-0419-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s00406-013-0419-y","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]}}}